Johnson Fistel, PLLP is investigating ORIC Pharmaceuticals following a 26% stock price drop after the company disclosed clinical trial data and dosing decisions. The firm is examining whether ORIC's executives complied with federal securities laws and is encouraging investors who suffered losses to join the investigation. This could lead to potential recovery of investor losses through legal action. Investors can contact Johnson Fistel for more information at no cost or obligation.
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
TransUnion has enhanced its mortgage credit report by integrating TruVision™ Alternative Credit Attributes (ACA 2.0) from FactorTrust® to provide lenders with broader insights beyond traditional credit data. This new data helps lenders identify borro...
